Metronidazol B. Braun (Metronidazole)

Metronidazole is reduced inside anaerobic microorganisms, producing reactive nitro radicals that damage DNA and inhibit nucleic acid synthesis. This selective activation in low‑oxygen environments leads to bacterial and protozoal cell death while sparing most human cells.

The appropriate dose of Metronidazol B. Braun is determined by the prescribing clinician based on the specific infection, patient weight, renal and hepatic function, and other clinical factors. Dosage regimens are individualized and should follow local prescribing guidelines.

Metronidazol B. Braun is classified as pregnancy category B, indicating that animal studies have not shown risk but there are limited human data. It may be used during pregnancy only if the potential benefit outweighs any risk. Metronidazole is excreted in breast milk; caution is advised and breastfeeding decisions should be made with a healthcare professional.

To order Metronidazol B. Braun, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Metronidazol B. Braun shares the same class mechanism as other nitroimidazoles such as tinidazole, but metronidazole has a longer history of clinical use and a broader spectrum against anaerobic bacteria and protozoa. Tinidazole may require less frequent dosing, while metronidazole is often preferred for severe intra‑abdominal infections due to extensive clinical data.

Metronidazol B. Braun should be stored at room temperature, protected from light and moisture, and kept in its original packaging. Do not freeze the solution. Before administration, inspect the vial for particulate matter and ensure proper aseptic technique during preparation.

Metronidazol B. Braun is given by intravenous infusion. The solution is typically diluted in compatible IV fluids and infused over a period determined by the prescribing clinician, usually ranging from 30 minutes to several hours, depending on the infection severity and patient tolerance.

Serious adverse events include seizures, peripheral neuropathy, severe allergic reactions such as anaphylaxis, and rare skin conditions like Stevens‑Johnson syndrome. Patients should be monitored for neurologic changes, rash, or breathing difficulties, and therapy should be stopped immediately if any of these occur.

Metronidazol B. Braun is contraindicated in individuals with a known hypersensitivity to metronidazole or other nitroimidazole compounds. Caution is also advised in patients with severe hepatic impairment, and it should be avoided in those with a history of seizures unless the benefits clearly outweigh the risks.